Since its release in 2017, dupilumab (a fully humanized monoclonal antibody that blocks IL-4 and IL-13) has transformed the therapeutic landscape for managing atopic dermatitis (AD) and other ...

Adults on dupilumab for severe chronic rhinosinusitis with nasal polyps had better outcomes than those who used omalizumab, ...

Dupilumab was approved by the FDA to treat bullous pemphigoid, that demonstrated its efficacy in achieving sustained disease ...

Dupilumab inhibits the signaling of IL-4 and IL-13, which are key mediators of type 2 inflammation and serve as important components in the pathogenesis of type 2 conditions in general.

achieving triple-action (IL-4/IL-13/ST2 inhibition) to address both dupilumab-responsive and refractory disorders, such as hypereosinophilic syndrome (HES). This mechanism establishes AK139 as a ...

DUBLIN , Nov. 20, 2023 /PRNewswire/ -- The "Dupilumab Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. This report offers comprehensive ...

By blocking IL-4 and IL-13 signaling, dupilumab rapidly reduced the abundance of S. aureus in patients with atopic dermatitis. Image: Adobe Stock. The study included 71 adults ...

USA: A recent case report published in The Open Dermatology Journal has brought attention to the successful use of ...

Dupilumab targets two specific cytokines — interleukin-4 (IL-4) and interleukin-13 (IL-13) — known to trigger skin issues. It stops them from talking to other cells, which then helps bring ...

[A]lthough our findings found that there is insufficient evidence to suggest that dupilumab use is associated with joint pain, the prevalence of joint pain observed among patients treated with ...

Dupilumab, a fully human monoclonal antibody, works by inhibiting the signaling of the interleukin 4 (IL-4) and IL-13 pathways and is approved for many conditions characterized by type 2 ...

ORLANDO, Fla. — The interleukin (IL)-4 and IL-13 inhibitor dupilumab improved itch symptoms and curtailed disease activity while also reducing oral corticosteroid use in older patients with ...